Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions

Future Medicinal Chemistry

Volumn 5, Issue 4, 2013, Pages 465-478

  Zamora, Pedro L ^a   Villamena, Frederick A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BETULIC ACID; CYCLOSPORIN A; DISUFENTON SODIUM; DOXORUBICIN; GKT 137831; MINOCYCLINE; REACTIVE NITROGEN SPECIES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; ROTENONE; RUTHENIUM; RUTHENIUM RED; UNCLASSIFIED DRUG; URSOLIC ACID;

CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL PROTECTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84875124407     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.15     Document Type: Review

References (135)

1. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs. preserved ejection fraction. Circ. J. 73(10), 1893-1900 (2009).
2. Rathi S, Deewania PC. The epidemiology and pathophysiology of heart failure. Med. Clin. North Am. 96(5), 881-890 (2012).
3. Rojas A, Mercadal E, Figueroa H, Morales M.A. Advanced glycation and ROS: a link between diabetes and heart failure. Curr. Vasc. Pharmacol. 6(1), 44-51 (2008).
4. Lalaoui MZ, El Midaoui A, de Champlain J, Moreau P. Is there a role for reactive oxygen species in arterial medial elastocalcinosis? Vasc. Pharmacol. 46(3), 201-206 (2007).
5. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur. J. Heart Fail. 11(5), 444-452 (2009).
6. Khaper N, Bryan S, Dhingra S et al. Targeting the vicious infammation-oxidative stress cycle for the management of heart failure. Antioxid. Redox Signal. 13(7), 1033-1049 (2010).
7. Murphy MP. How mitochondria produce reactive oxygen species. Biochem. J. 417(Pt 1), 1-13 (2009).
8. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med. 29(3-4), 222-230 (2000).
9. Muller F. The nature and mechanism of superoxide production by the electron transport chain: its relevance to aging. Age 23(4), 227-253 (2000).
10. Turrens J, McCord J. Mechanisms and consequences of tissue injury. CV Mosby Co., MI, USA (1990).
11. Turrens JF. Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 17(1), 3-8 (1997).
12. Keyer K, Imlay JA. Superoxide accelerates DNA damage by elevating free-iron levels. Proc. Natl Acad. Sci. USA 93(24), 13635-13640 (1996).
13. Aon MA, Cortassa S, Marban E, O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by local release of reactive oxygen species in cardiac myocytes. J. Biol. Chem. 278(45), 44735-44744 (2003).
14. Hamer I, Wattiaux R, Wattiaux-De Coninick S. Deleterious effects of xanthine oxidase on rat liver endothelial cells after ischemia/reperfusion. Biochim. Biophys. Acta 1269(2), 145-152 (1995).
15. Li Y-L, Zheng H. Angiotensin-II-NADPH oxidase-derived superoxide mediates diabetes-Attenuated cell excitability of aortic baroreceptor neurons. Am. J. Physiol. Cell Physiol. 301(6), C1368-C1377 (2011).
16. Kliment CR, Oury TD. Extracellular superoxide dismutase protects cardiovascular syndecan-1 from oxidative shedding. Free Radic. Biol. Med. 50(9), 1075-1080 (2011).
17. Vavrova A, Popelova O, Sterba M et al. In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxcicity. Arch. Toxicol. 85(5), 525-535 (2011).
18. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N. Engl. J. Med. 357(11), 1121-1135 (2007).
19. Filomeni G, Rotillo G, Ciriolo MR. Disulfde relays and phosphorylative cascades: partners in redox-mediated signaling pathways. Cell Death Differ. 12 (12), 1555-1563 (2005).
20. Sadoshima J. Redox regulation of growth and death in cardia myocytes. Antioxid. Redox Signal. 8(9-10), 1621-1624 (2006).
21. Fu C, Hu J, Liu T, Ago T, Sadoshima J, Li H. Qualitative analysis of redox-sensitive proteome with DIGE and ICAT. J. Proteome. Res. 7(9), 3789-3802 (2008).
22. Opie LH. Reperfusion injury and its pharmacologic modifcation. Circulation 80(4), 1049-1062 (1989).
23. Robin E, Guzy RD, Loor G et al. Oxidant stress during simulated ischemia primes cardiomyocytes for cell death during reperfusion. J. Biol. Chem. 282(26), 19133-19143 (2007).
24. Blasig IE, Dickens BF, Weglicki WB, Kramer JH. Uncoupling of mitochondrial oxidative phosphorylation alters lipid peroxidation-derived free radical production but not recovery of postischemic rat hearts and post-hypoxic endothelial cells. Mol. Cell. Biochem. 160-161, 167-177 (1996).
25. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11(1), 81-128 (1991).
26. Chen J, Henderson GI, Freeman GL. Role of 4-hydroxynonenal in modifcation of cytochrome c oxidase in ischemia/reperfused rat heart. J. Mol. Cell. Cardiol. 33(1), 1919-1927 (2001).
27. Assaly R, de Tassigny A, Paradis S, Jacquin S, Berdeaux A, Morin D. Oxidative stress, mitochondrial permeability transition pore opening and cell death during hypoxia-reoxygenation in adult cardiomyocytes. Eur. J. Pharmacol. 675(1-3), 6-14 (2012).
28. White RJ, Reynolds IJ. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specifc to excitotoxin exposure. J. Neurosci. 16(18), 5688-5697 (1996).
29. Honda HM, Ping P. Mitochondrial permeability transition in cardiac cell injury and death. Cardiovasc. Drugs Ther. 20(6), 425-432 (2006).
30. Regula KM, Krishenbaum LA. Apoptosis of ventricular myocytes: a means to an end. J. Mol. Cell. Cardiol. 38(1), 3-13 (2005).
31. Luetjens CM, Bui NT, Sengpiel B et al. Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. J. Neurosci. 20 (15), 5715-5723 (2000).
32. Correa F, Soto V, Zazueta C. Mitochondrial permeability transition relevance for apoptotic triggering in the post-ischemic heart. Int. J. Biochem. Cell Biol. 39(4), 787-798 (2007).
33. Farbstein D, Kozak-Blickstein A, Levy AP. Antioxidant vitamins and their use in preventing cardiovascular disease. Molecules 15 (11), 8098-8110 (2010).
34. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br. J. Dermatol. 134(4), 693-695 (1996).
35. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl Acad. Sci. USA 95(26), 15769-15774 (1998).
36. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces infammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl Acad. Sci. USA 96(23), 13496-13500 (1999).
37. Amin AR, Attur MG, Thakker GD et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl Acad. Sci. USA 93 (24), 14014-14019 (1996).
38. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem. 94(3), 819-827 (2005).
39. Grieseler A, Schultze AT, Kupsch K et al. Inhibitory modulation of the mitochondrial permeability transition by minocycline. Biochem. Pharmacol. 77(5), 888-896 (2009).
40. Zhu S, Stavrovskaya IG, Drozda M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417(6884), 74-78 (2002).
41. Fernandez-Gomez FJ, Galindo MF, Gomez-Lazara M et al. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 133(4), 959-967 (2005).
42. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc. Drugs Ther. 24(1), 85-87 (2010).
43. Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HH. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J. Pharmacol. Exp. Ther. 304(1), 425-432 (2003).
44. Kloner RA, Hale SL, Wangde D et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J. Am. Heart Assoc. 1, e001644 (2012).
45. Zhao K, Zhao GM, Wu D et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem. 279(33), 34682-34690 (2004).
46. Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem. Pharmacol. 70(12), 1796-1806 (2005).
47. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 341(2), 233-249 (1999).
48. 2+ signaling between sarco-endoplasmic reticulum and mitochondria. J. Physiol. 529(Pt 1), 69-81 (2000).
49. Ferrari R, di Lisa F, Raddino R, Visioli O. The effects of ruthenium red on mitochondrial function during post-ischaemic reperfusion. J. Mol. Cell. Cardiol. 14 (12), 737-740 (1982).
50. 2+]m overload in rat hearts. Am. J. Physiol. 271(5 Pt 2), H2145-H2153 (1996).
51. Velasco I, Tapia R. Alternations of intracellular calcium homeostasis and mitochondrial function are involved in ruthenium red neurotoxicity in primary cortical cultures. J. Neurosci. Res. 60(4), 543-551 (2000).
52. Zhou Z, Bers DM. Time course of action of antagonists of mitochondrial Ca uptake in intact ventricular myocytes. Pfugers. Arch. 445(1), 132-138 (2002).
53. 360, a specifc mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo. Br. J. Pharmacol. 149(7), 829-837 (2006).
54. Brandes R P, Weissmann N, Schroder K. NADPH oxidases in cardiovascular disease. Free Radic. Biol. Med. 49(5), 687-706 (2012).
55. Guzik TJ, Sadowski J, Guzik B et al. Coronary artery superoxide production and NOX isoform expression in human coronary artery disease. Arterioscl. Throm. Vas. 26, 333-339 (2006).
56. Zhang Y, Tocchetti CG, Krieg T, Moens AL. Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radic. Biol. Med. 53(8), 1531-1540 (2012).
57. Ago T, Kitazono T, Ooboshi H et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109(2), 227-233 (2004).
58. Xu H, Goettsch C, Xia N et al. Differential roles of PKCalpha an PKCepsilon in controlling the gene expression of Nox4 in human endothelial cells. Free Radic. Biol. Med. 44(8), 1656-1667 (2008).
59. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc. Res. 65(2), 495-504 (2005).
60. Griendling KK. Novel NAD(P)H oxidases in the cardiovascular system. Heart 90, 491-493 (2004).
61. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc. Natl Acad. Sci. USA 107 (35), 15565-15570 (2010).
62. Takac I, Schroder K, Zhang L et al. The E-loop is invoved in hydrogen peroxide formation by the NADPH oxidase Nox4. J. Biol. Chem. 286(15), 13304-13313 (2011).
63. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, Gorlach A. NOX2 and NOX4 mediate proliferative responses in endothelial cells. Antioxid. Redox Sign. 8 (9-10), 1473-1484 (2006).
64. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J. Mol. Cell. Cardiol. 50(3), 408-416 (2011).
65. von Lohneysen K, Noack D, Wood MR, Friedman JS, Knauss UG. Structural insights into Nox4 and Nox2: motifs involved in function and cellular localization. Mol. Cell. Biol. 30(4), 961-975 (2010).
66. Nisimoto Y, Jackson HM, Ogawa H, Kawahara T, Lambeth JD. Constituitive NADPH-depedent electron transferase activity of the Nox4 dehydrogenase domain. Biochemistry 49(11), 2433-2442 (2010).
67. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I. Classical inhibitors of NOX NAD(P)H oxidases are not specifc. Curr. Drug Metab. 9(8), 686-696 (2008).
68. O'Donnell BV, Tew DG, Jones OT, England PJ. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem. J. 290(Pt 1), 41-49 (1993).
69. Wind S, Beuerlein K, Eucker T et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 161(4), 885-898 (2012).
70. Takemato M, Node K, Nakagami H et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108(10), 1429-1437 (2001).
71. Danesh FR, Sadeghi MM, Amro N et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic neuropathy. Proc. Natl Acad. Sci. USA 99(12), 8301-8305 (2002).
72. Rikitake L, Liao JK. Rho, GTPases, statins, and nitric oxide. Circ. Res. 97(12), 1232-1235 (2005).
73. Naseef WM. Assembly of the phagocyte NADPH oxidase. Histochem. Cell Biol. 122(4), 277-291 (2004).
74. Kwok JMF, Cheng-Hwa Ma C, Ma S. Recent developments in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase. Vasc. Pharmacol. 58, 21-30 (2013).
75. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339(19), 1349-1357 (1998).
76. Gaggini F, Laleu B, Orchard M et al. Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine,-pyrazine and-oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. Bioorg. Med. Chem. 19(23), 6989-6999 (2011).
77. Jiang JX, Chen X, Serizawa N et al. Liver fbrosis and hepatocyte apoptosis are attenuated by GKT137831 a novel NOX4/NOX1 inhibitor in vivo. Free Radic. Biol. Med. 53(2), 289-296 (2012).
78. Maalouf RM, Eid AA, Gorin YC et al. Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. Am. J. Physiol. Cell. Physiol. 302(3), C597-C 604 (2012).
79. Siuda D, Zechner U, Hajj NE et al. Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells. Basic Res. Cardiol. 107(5), 283 (2012).
80. Su GH, Sohn TA, Ryu B, Kern SE. A novel histone deacetylase inhibitor identifed by high-throughput transcriptional screening of a compound library. Cancer Res. 60 (12), 3137-3142 (2000).
81. Csanyi G, Cifuentes-Pagano E, Ghouleh IA et al. Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic. Biol. Med. 51 (6), 1116-1125 (2011).
82. - and systolic blood pressure in mice. Circ. Res. 89(5), 408-414 (2001).
83. Cary SP, Winger JA, Derbyshire ER, Marletta M.A. Nitric oxide signaling: no longer simply on or off. Trends Biochem. Sci. 31(4), 231-239 (2006).
84. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol. Rev. 89(2), 481-534 (2009).
85. Stamler JS, Lamas S, Fang FC. Nitrosylation; the prototypic redox-based signaling mechanism. Cell 106(6), 675-683 (2001).
86. Matoba T, Shimokawa H, Kubota H et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem. Biophys. Res. Commun. 290(3), 909-913 (2002).
87. Taverne YJ, de Beer VJ, Hoogteijling BA et al. Nitroso-redox balance in control of coronary vasomotor tone. J. Appl. Physiol. 112 (10), 1644-1652 (2012).
88. Wei CC, Crane BR, Stuehr DJ. Tetrahydrobiopterin radical enzymology. Chem. Rev. 103(6), 2365-2383 (2003).
89. Bevers LM, Braam B, Post JA et al. Tetrahydrobiopterin, but not l-Arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 47(1), 87-94 (2006).
90. Sugiyama T, Levy BD, Michel T. Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. J. Biol. Chem. 284(19), 12691-12700 (2009).
91. Meininger CJ, Marinos RS, Hatakeyama K et al. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin defciency. Biochem. J. 349(Pt 1), (2000).
92. Sartoretto JL, Kalwa H, Pluth MD, Lippard SJ, Michel T. Hydrogen peroxide differentially modulates cardiac myocyte nitric oxide synthesis. Proc. Natl Acad. Sci. USA 108(38), 15792-15797 (2011).
93. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97(12), 1129-1135 (1998).
94. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103(1), 113-118 (2001).
95. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attentuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20(1), 61-69 (2000).
96. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobipterin in vascualar endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23(1), 176-182 (2003).
97. Steinkamp-Fenske K, Bollinger L, Voller N et al. Ursolic acid from the Chinese herb danshen (Salvia miltiorrhiza L.) upregulates eNOS and downregulates Nox4 expression in human endothelial cells. Atherosclerosis 195 (1), e104-e111 (2007).
98. Steinkamp-Fenske K, Bollinger L, Xu H et al. Reciprocal regulation of endothelial nitric-oxide synthase and NADPH oxidase by betulinic acid in human endothelial cells. J. Pharacol. Exp. Ther. 322(2), 836-842 (2007).
99. Zweier JL, Villamena FA. Chemistry of free radicals in biological systems. In: Oxidative Stress and Cardiac Failure. Kukin ML, Fuster V (Eds). Futura Publishing Co., NY, USA, 67-95 (2003).
100. Esposito L, Raber J, Kekonius L et al. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J. Neurosci. 26(19), 5167-5179 (2006).
101. Chi LG, Tamura Y, Hoff PT et al. Effect of superoxide dismutase on myocardial infarct size in the canine heart after 6 h of regional ischemia and reperfusion: a demonstration of myocardial salvage. Circ. Res. 64(4), 665-675 (1989).
102. Kilgore KS, Friedrichs GS, Johnson CR et al. Protective effects of the SOD-mimetic SC-52608 against ischemia/reperfusion damage in the rabbit isolated heart. J. Mol. Cell. Cardiol. 26(8), 995-1006 (1994).
103. Bognar Z, Kalai T, Palf A et al. A novel SOD-mimetic permeability transition inhibitor protects ischemic heart by inhibiting both apoptotic and necrotic cell death. Free Radic. Biol. Med. 41(5), 835-848 (2006).
104. Przyklenk K, Kloner RA. "Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood fow. Circ. Res. 64(1), 86-96 (1989).
105. Flaherty J T, Pitt B, Gruber JW et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 89 (5), 1982-1991 (1994).
106. Stephens NG, Parsons A, Schofeld PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347(9004), 781-786 (1996).
107. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N. Engl. J. Med. 342(3), 154-160 (2000).
108. Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians' Health Study II randomized controlled trial. JAMA 300(18), 2123-2133 (2008).
109. Rodrigo R, Prieto JC, Castillo R. Cardioprotection against ischemia/reperfusion by vitamins C and E plus n-3 fatty acids: molecular mechanisms and potential clinical applications. Clin. Sci. (Lond.) 124(1), 1-15 (2013).
110. Jackson TS, Xu A, Vita JA, Keaney JFJ. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ. Res. 83(9), 916-922 (1998).
111. Tosaki A, Braquet P. DMPO and reperfusion injury: arrhythmia, heart function, electron spin resonance, and nuclear magnetic resonance studies in isolated working guinea pig hearts. Am. Heart J. 120(4), 819-830 (1990).
112. Zuo L, Chen Y, Reyes LA et al. The radical trap 5, 5-dimethyl-1-pyrroline N-oxide exerts dose-dependent protection against myocardial ischemia-reperfusion injury through preservation of mitochondrial electron transport. J. Pharmacol. Exp. Ther. 329(2), 515-523 (2009).
113. Das A, Gopalakrishnan B, Voss OH, Doseff A, Villamena FA. Inhibition of ROS-induced apoptosis in endothelial cells by nitrone sping traps via induction of phase II enzymes and suppression of mitochondria-dependent pro-Apoptotic signaling. Biochem. Pharmacol. 84(4), 486-497 (2012).
114. Lees KR, Zivin JA, Ashwood T et al. NX Y-059 for acute ischemic stroke. N. Engl. J. Med. 354(6), 588-600 (2006).
115. Shuaib A, Lees KR, Lyden P et al. N X Y-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 357(6), 562-571 (2007).
116. 60 as a radical sponge. J. Am. Chem. Soc. 114 (11), 4412-4414 (1992).
117. 60) derivatives as nonviral gene-delivery vectors. Mol. Pharm. 5(4), 567-578 (2008).
118. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 5(12), 2578-2585 (2005).
119. Dugan LL, Turetsky DM, Du C et al. Carboxyfullerenes as neuroprotective agents. Proc. Natl Acad. Sci. USA 94(17), 9434-9439 (1997).
120. 60) fulleropyrrolidine-thalidomide dyad as a new anti-infammation agent. Bioorg. Med. Chem. 16(18), 8619-8626 (2008).
121. Li W, Zhao L, Wei T, Zhao Y, Chen C. The inhibition of death receptor mediated apoptosis through lysosome stabilization following internalization of carboxyfullerene nanoparticles. Biomaterials 32 (16), 4030-4041 (2011).
122. 60 (FC4S) in anesthetized rats during coronary occlusion/reperfusion injury. Drug Develop. Res. 53(4), 244-253 (2001).
123. 24 prevents doxorubicin-induced acute cardiotoxicity in rats. Pharmacol. Rep. 62(4), 707-718 (2012).
124. Yin J-J, Lao F, Fu PP et al. The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials 30 (4), 611-621 (2009).
125. Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56(2), 185-229 (2004).
126. Takada H, Kokubo K, Matsubayashi K, Oshima T. Antioxidant activity of supramolecular water-soluble fullerenes evaluated by beta-carotene bleaching assay. Biosci. Biotechnol. Biochem. 70(12), 3088-3093 (2006).
127. Shen W, Liu K, Tian C et al. R-Alpha-lipoic acid and acetyl-L-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes. Diabetologia 51(1), 165-174 (2008).
128. Shen W, Hao J, Tian C et al. A combination of nutriments improves mitochondrial biogenesis and function in skeletal muscle of type 2 diabetic Goto-Kakizaki rats. PLoS ONE 3(6), e2328 (2008).
129. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr. Rev. 66(11), 646-657 (2008).
130. Lee HA, Hughes DA. Alpha-lipoic acid modulates NF-kB activity in human monocytic cells by direct interaction with DNA. Exp. Gerontol. 37(2-3), 401-410 (2002).
131. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 1790 (10), 1149-1160 (2009).
132. Hotamisligil GS. Endoplasmic reticulum stress and the infammatory basis of metabolic disease. Cell 140(6), 900-917 (2010).
133. Jiang Z, Hu Z, Zeng L et al. The role of the Golgi apparatus in oxidative stress: is this organelle less signifcant than mitochondria? Free Radic. Biol. Med. 50(8), 907-917 (2011).
134. 2+) handling. PLoS ONE 7(12), e52005 (2012).
135. Kim SH, Kim SH, Choi M et al. Natural therapeutic magnesium lithospermate B potently protects the endothelium from hyperglycemia-induced dysfunction. Cardiovasc. Res. 87(4), 713-722 (2010).